section name header

Pronunciation

SEM-ip-LI-mab

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: monoclonal antibodies, programmed death-1 inhibitors

Indications

High Alert


Action

  • Programmed death receptor-1 (PD-1) blocking antibody (an IgG4 kappa immunoglobulin) that binds to PD-1 and blocks its interaction with its ligands, PD-L1 and PD-L2, resulting in activation of the immune system and decreased tumor growth.
Therapeutic effects:
  • Decreased progression of metastatic or locally advanced cutaneous squamous cell carcinoma or basal cell carcinoma.
  • Improved survival in NSCLC.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Minimally distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 19 days

Time/Action Profile

(response)

ROUTEONSETPEAKDURATION
IVwithin 6 mounknownmay persist for 8 mo





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: IMMUNE-MEDIATED MYOCARDITIS, immune-mediated pericarditis, immune-mediated vasculitis

Derm: pruritus, rash, IMMUNE-MEDIATED DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), IMMUNE-MEDIATED STEVENS-JOHNSON SYNDROME (SJS), IMMUNE-MEDIATED TOXIC EPIDERMAL NECROLYSIS (TEN)

EENT: immune-mediated iritis, immune-mediated uveitis

Endo: immune-mediated hypothyroidism, hypoparathyroidism, IMMUNE-MEDIATED ADRENAL INSUFFICIENCY, immune-mediated hyperthyroidism, immune-mediated hypophysitis, immune-mediated type 1 diabetes

F and E: hyponatremia, hypophosphatemia

GI: constipation, appetite, diarrhea, nausea, IMMUNE-MEDIATED COLITIS, immune-mediated gastritis, IMMUNE-MEDIATED HEPATITIS, immune-mediated pancreatitis

GU: immune-mediated nephritis

Hemat: anemia, immune-mediated hemolytic anemia, lymphopenia

MS: pain, immune-mediated myositis, IMMUNE-MEDIATED RHABDOMYOLYSIS

Neuro: autoimmune neuropathy, IMMUNE-MEDIATED ENCEPHALITIS, immune-mediated Guillain-Barré syndrome, IMMUNE-MEDIATED MENINGITIS, immune-mediated myasthenic syndrome, immune-mediated myelitis, fatigue

Resp: IMMUNE-MEDIATED PNEUMONITIS

Misc: INFUSION-RELATED REACTIONS

Interactions

Drug-drug:

Route/Dosage

Locally Advanced/Metastatic Squamous Cell Carcinoma or Locally Advanced/Metastatic Basal Cell Carcinoma

Non-Small Cell Lung Cancer

Availability

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Libtayo